Related Experiment Video
Updated: Mar 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension
Whitney L Petrilli1, Scott B Hoyt1, Clare London1
1Departments of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism & Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories , Rahway, New Jersey 07065, United States.
Abstract:
Herein we report the discovery and hit-to-lead optimization of a series of spirocyclic piperidine aldosterone synthase (CYP11B2) inhibitors. Compounds from this series display potent CYP11B2 inhibition, good selectivity versus related CYP enzymes, and lead-like physical and pharmacokinetic properties.
More Related Videos
10:17Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones
Published on: February 7, 2019
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hypertension IV: Drug Therapy and Lifestyle Modifications